Another approved therapy for patients with TRK fusion–positive cancers is the multikinase inhibitor entrectinib, which showed an ORR of 69% in 13 patients with lung cancer and a median PFS and OS of 14.9 months at a median follow-up of 14.2 months.20 This evidence concerns the gene NTRK1 and cancer.